The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

• Authors: PERUSINI Maria Agustina; PAGNANO Katia; PAVLOVSKY Carolina; ŽÁČKOVÁ Daniela; MAYER Jiří; MOIRAGHI Beatriz; VARELA Ana Ines; BIANCHINI Michele; BEATRIZ Pascoal Lopes Ana; DUARTE Gislaine; ANTONIO De Souza Carmino; JEŽÍŠKOVÁ Ivana; HRONSKÁ Anežka; JURČEK Tomáš; HYE Won Lee; CHANG Myung Hee; MEDEIROS Jessie J F; ABELSON Sagi; KIM Dennis Dong Hwan
• Year of publication: 2026
• Type: Peer-reviewed scientific article
• Magazine / Source: Leukemia
• MU Faculty or unit: Faculty of Medicine
• web: https://www.nature.com/articles/s41375-026-02921-6
• Doi: https://doi.org/10.1038/s41375-026-02921-6